• Jordan K Schaefer, Mengbing Li, Zhenke Wu, Tanima Basu, Geoffrey D Barnes, Marc Carrier, Jennifer J Griggs, and Suman L Sood.
• Department of Medicine, Division of Hematology/Oncology, University of Michigan, C366 Med Inn Building, 1500 E. Medical Center Drive, Ann Arbor, MI, 48109, USA. jschaef@med.umich.edu.
• J. Thromb. Thrombolysis. 2021 Jul 1; 52 (1): 214-223.

AbstractCancer associated thrombosis (CAT) is a leading cause of death among patients with cancer. It is not clear if non-clinical factors are associated with anticoagulation receipt. We conducted a retrospective cohort study of Optum's de-identified Clinformatics® Database of adults with cancer diagnosed between 2009 and 2016 who developed CAT, treated with an outpatient anticoagulant (warfarin, low molecular weight heparin (LMWH), or a direct oral anticoagulant (DOAC)). Of 12,622 patients, three months after an episode of CAT, 1,485 (12%) were on LMWH, 1,546 (12%) on DOACs, and 9,591 (76%) were on warfarin. When controlling for other factors, anticoagulant use was significantly associated with socioeconomic factors, region, co-morbidities, type of thrombosis, and cancer subtype. Patients with a bachelor's degree or greater level of education were less likely to receive warfarin (OR: 0.77; 95% CI: [0.59, 0.99]; p < 0.046) or DOACs (OR: 0.67; 95% CI: [0.55, 0.82]; p < 0.001) compared to LMWH. Patients with higher income levels were more likely to receive LMWH or DOACs compared to warfarin, while patients across all income levels were equally likely to receive LMWH or DOACs. Non-clinical factors including income, education, and region, are associated with anticoagulation receipt three months after an episode of CAT. Sociodemographic factors may result in some patients receiving suboptimal care and contribute to non-guideline concordant care for CAT.© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature.

5 keywords...

hide…